South Africa’s healthcare system stands at a pivotal moment. As it aims to strengthen access to affordable, quality medicines for all citizens, regulatory reform has become a cornerstone of national health discourse. Regulatory bodies such as the South African Health Products Regulatory Authority (SAHPRA) play a critical role in ensuring that patients receive safe, effective, and affordable treatment, but that role is becoming increasingly complex. The balance between innovation and access, speed and safety, and global alignment and local responsiveness must now be carefully managed to build a healthcare system that is both resilient and equitable [1][2].
The COVID-19 pandemic revealed the vulnerabilities in regulatory systems worldwide, while also highlighting the potential for more agile, coordinated, and science-driven responses. In South Africa, SAHPRA’s rapid approval of COVID-19 diagnostics, vaccines, and therapeutics demonstrated its capacity for flexibility [2]. These efforts have reignited discussions about how regulatory systems can, and should, evolve to better meet future challenges.
The importance of regulatory harmonisation has gained renewed momentum across low- and middle-income countries. Globally, agencies like the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) have developed reliance-based review systems that enable regulators to use trusted international decisions to accelerate local approvals without compromising safety standards [3]. The World Health Organization (WHO) has championed this approach through its Collaborative Registration Procedure and benchmarking tools for national regulatory authorities [4].. These models provide a roadmap for countries like South Africa to modernise regulatory pathways in alignment with international best practices while tailoring implementation to local capacity [1][6].
SAHPRA has already made significant strides in this direction. The introduction of risk-based review models, prioritisation frameworks for essential medicines, and a growing commitment to reliance mechanisms, particularly within the Southern African Development Community (SADC), mark important progress. For example, SAHPRA is a participating member of the ZAZIBONA initiative, a collaborative medicines registration project among SADC countries that aims to streamline the review process for common applications. However, the operationalisation of these models requires more than regulatory intent; it demands investment in people, systems, and digital infrastructure [2].
South Africa’s regulatory authority inherited a large backlog of unprocessed applications when it replaced the former Medicines Control Council (MCC). While the Backlog Clearance Project has achieved notable success in reducing the number of pending applications, systemic bottlenecks remain. These include limited human resource capacity, manual dossier processing, complex submission requirements, and challenges in integrating real-time data systems. The combination of these factors contributes to long approval timelines, particularly for generic and biosimilar medicines, which are vital to ensuring affordability in the public and private sectors [2][5].
A modern regulatory framework must be equipped not only to respond to emergencies but also to enable timely access to innovations. South Africa’s medicine pipeline increasingly includes new-generation biologics, gene therapies, and digital health interventions that do not fit traditional review models. The ability to assess complex technologies requires upskilling regulatory staff, investing in clinical and pharmacovigilance expertise, and leveraging cross-border data-sharing agreements [1][5]. Regulatory agility should not mean compromising strictness but rather rethinking how strictness can be delivered more efficiently [3].
One promising avenue is the digital transformation of regulatory systems. Countries such as Rwanda and Ghana have piloted e-submission platforms, automated tracking tools, and digital evaluation templates that allow for real-time monitoring of regulatory workflows. These platforms improve transparency, reduce processing times, and enable better communication with applicants. For SAHPRA, full implementation of a digital backbone would not only improve efficiency but could also position South Africa as a regional regulatory hub [2][6].
At the same time, strengthening the enabling environment around regulation is essential. Efficient regulatory decision making must be supported by coherent health policy, a predictable procurement system, and inter-agency coordination. When delays in medicine registration coincide with procurement challenges, as seen in recent oncology and HIV treatment disruptions, the result is a double barrier to access. Bridging innovation and access therefore requires that regulatory agencies be integrated into broader health system strengthening strategies [1][2].
Public trust in regulatory decisions is also paramount. In an age of growing misinformation, particularly around medicines and vaccines, transparency and public engagement are critical [5]. SAHPRA’s public reports, safety alerts, and stakeholder forums have laid a foundation, but sustained communication campaigns, particularly in multiple languages and across underserved areas, can deepen public confidence. Trust is not built through decisions alone, but through visible accountability and inclusive engagement.
To position South Africa’s regulatory system as a driver of equitable access, several priorities emerge. Firstly, SAHPRA’s resourcing must be secured with long-term budget allocations, not just short-term project funding. Secondly, investments in digital infrastructure must be accompanied by training programmes and workflow redesigns to ensure adoption. Third, partnerships with academic institutions, global regulators, and the private sector should be scaled to support knowledge exchange and technical capacity [1][5].
Finally, regulation must be seen not as a gatekeeping function, but as a catalyst for access. Every medicine approval is a potential lifesaving intervention delayed or delivered. The question is not whether to modernise regulation, but how urgently and equitably it can be done.
As South Africa looks to the future of healthcare, regulatory reform offers a strategic opportunity to close access gaps, improve health outcomes, and enable sustainable innovation. The bridge between science and society is built one decision at a time, through a regulatory system that is accountable, empowered, and future focused [1][2][6].
References
[1] World Health Organization. “Good Regulatory Practices: Guidelines for National Regulatory Authorities.” 2021.
[2] SAHPRA. “Annual Performance Plan 2023/24.” www.sahpra.org.za
[3] EMA. “Regulatory Science Strategy to 2025.” European Medicines Agency, 2020.
[4] WHO Collaborative Registration Procedure. “CRP Guidelines.” World Health Organization.
[5] Griffith MM, Gross AE, Sutton SH. “The Role of the Regulatory Authority in Health System Strengthening.” Clinical Therapeutics, 2019.
[6] Medicines Regulatory Harmonization in Africa. African Union Development Agency (AUDA-NEPAD), 2022.
[7] SAHPRA. “Backlog Clearance Programme Report.” www.sahpra.org.za